Search

In the 50 months preceding March 1995, 35 adult patients underwent aortic valve replacement with a cryopreserved human aortic valve allograft. Nine of these patients had active endocarditis. The remaining 26 patients had aortic valve pathology without active infection. This study consists of a comparison of these two groups.One of the patients with active infection underwent inclusion technique replacement of the infected valve. The other eight valves were replaced with root-replacement technique. Of the 26 non-infected patients, 4 valves were replaced with the inclusion technique, and the remaining 22 were replaced with the root-replacement technique. None of the patients are maintained on long-term anti-coagulation.We have followed the infected group an average of 32 months and the group without active infection has been followed an average of 27 months. There were two perioperative deaths in the nine patients with infected valves and no deaths in the group without active infection (Pearson's chi2 p0.05). There have been no thromboembolic complications and no recurrent infections.

The authors compared blood loss, transfusion requirements, and heparin doses for reoperative cardiac surgery using either: a) a Duraflow (Baxter Corporation, Irvine, CA) heparin coated cardiopulmonary bypass (CPB) system or b) standard CPB. Twenty patients underwent redo cardiac surgery while supported with heparin coated CPB, and 17 patients underwent redo cardiac surgery with standard CPB. The following data are presented as mean +/- standard deviation. The heparin coated CPB circuit group received significantly less heparin than the standard CPB group (322 +/- 80 IU/kg versus 448 +/- 80 IU/kg, p0.01). There was no difference in blood loss in the first 24 postoperative hrs or mean transfusion requirements for the two groups. Despite the reduced dose of heparin, the mean activated clotting time in the heparin coated group was similar to the mean activated clotting time of the standard CPB group (577 +/- 98 sec versus 612 +/- 117 sec, p = ns). In conclusion, heparin coated CPB without reduced activated clotting time does not reduce transfusion requirements or blood loss in reoperative cardiac surgery. The heparin coated CPB system allows maintenance of the activated clotting time level despite reduced heparin doses.

We compared an equine antithymocyte globulin (ATGAM)-based protocol with a Minnesota antilymphocyte globulin (MALG)-based protocol and a murine monoclonal CD-3 (OKT-)-based protocol in 3 groups of heart transplant (HT) recipients. Thirty-four recipients received a four-day course of ATGAM. Thirty HT recipients received a 14-day course of OKT3. Fifteen HT recipients received MALG for an average of 10 days. The ATGAM group received cyclosporine beginning preoperatively, while the OKT3 and MALG groups received CyA beginning on post-transplant day 4. All three groups received identical azathioprine and similar steroid therapy. The 3 groups were similar in age, donor/recipient HLA mismatches, and donor/recipient gender mismatches. The MALG and OKT3 groups had 20% and 17% females, respectively, while the ATG group had 41% (p0.05). Average follow-up exceeded 14 months for each group. The ATGAM group received a higher dose of CyA during "induction" therapy than the OKT3 and MALG groups, and experienced a greater rise in post-transplant serum creatinine levels. We found no difference between the 3 groups in: preoperative creatinine levels, one-year post-transplant creatinine levels, number of patients who could be successfully "weaned" from steroids, or one-year survival. Other data are tabulated as episodes/patient: [table: see text] We conclude that ATG plus preoperative CyA is superior for rejection prophylaxis following heart transplantation when compared with either MALG plus postoperative CyA or OKT3 plus postoperative CyA.

The superior vena cava (SVC) and thoracic inferior vena cava (IVC) were replaced in 46 dogs with autologous vein, knitted Dacron, glutaraldehyde-fixed porcine pericardium, unsupported polytetrafluorethylene (PTFE), and externally stented PTFE. After 30 days, patency rates were determined by contrast venography and were 100%, 9%, 50%, 75%, and 100%, respectively. The patency rates of Dacron and glutaraldehyde-fixed pericardium are considered unacceptable when compared to autologous vein (p less than 0.05). Stented PTFE exhibited a patency rate equal to that of autologous vein at 30 days, minimal graft reaction, excellent incorporation by host fibroblasts, and a smooth neointima. The external spiral support added to PTFE enchanced the thromboresistance of this graft in the thoracic venous system. Long-term follow-up is required to determine if the stented PTFE prosthesis remains comparable to autologous vein as a venous conduit.